Company intelligence / Profile preview

Hemab Therapeutics

Cambridge, Massachusetts, United Stateshemab.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 2

Overview

Hemab Therapeutics develops first-in-class prophylactic antibody therapies targeting rare and underserved bleeding and thrombotic disorders. Their lead program, HMB-002, a monovalent human antibody targeting the C-terminal CK domain of VWF for Von Willebrand Disease, aims to boost endogenous VWF levels without impairing function. Preclinical data show promising therapeutic potential. The company pursues a strategic "1–2–5" plan to develop five clinical assets by 2025 addressing multiple rare blood clotting diseases[1][3][5].

Therapeutic areas: HematologyRare Diseases
Modalities: Monoclonal antibodiesBispecific antibodies
Industry: Biotech

Drug pipeline

4 assets

HMB-002

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hemab Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemab Therapeutics.

Explore the full profile